The UK and US have agreed to a significant trade agreement that will keep no duties on UK pharmaceutical shipments being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise funding on medicines through the NHS. This commitment secures that tariffs on these crucial exports will remain at zero for a timeframe of three years.
This deal follows previous statements to hike tariffs on patented pharmaceutical imports, with potential rates discussed up to one hundred percent.
"This agreement with the UK strengthens the global environment for innovative medicines and brings long-overdue balance to American-British pharmaceutical trade," an announcement said.
Economic Importance
Pharmaceuticals are one of the the United Kingdom's largest goods shipped to the United States, which is easily the primary buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months to the end of September, the UK exported drugs valued at over eleven billion pounds to the US. This figure accounted for 17.4% of total UK exports in that timeframe.
"This deal secures jobs, boosts investment and sets the stage for the UK to become a worldwide center for biotech and pharma," a government official remarked.
Key UK Commitments
The deal includes several specific pledges from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase total NHS spending on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must return to the NHS to control costs will be restricted at 15%. Last year, rebates exceeded 20%.
Recent Tensions
The pact comes amid a long-running row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by arguments that American patients were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been halted or scrapped, while substantial funding commitments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
